Eta Shinichi, Kawahara Motoshi
Department of Urology, Graduate School of Medicine and Dentistry, Kagoshima University, 8-35-1 Sakura-ga-oka, Kagoshima 890-8520, Japan.
Jpn J Antibiot. 2006 Feb;59(1):21-8.
Using the agar dilution method, the antibacterial activity of 18 antibiotics inclusive of 4 carbapenems were investigated against 101 strains of urinary pathogens isolated from patients with urinary tract infections who visited the Department of Urology at Kagoshima University Hospital, between January and December 2002. 4 strains of Staphylococcus aureus, 3 strains of Staphylococcus spp. (exclusive of S. aureus), 14 strains of Enterococcus faecalis, 3 strains of Enterococcus spp. (exclusive of E. faecalis), 41 strains of Escherichia coli, 21 strains of Enterobacteriaceae (exclusive of E. coli), 12 strains of Pseudomonas aeruginosa and 3 strains of glucose-nonfermentative Gram-negative rods (exclusive of P. aeruginosa) were examined. 1. Against clinical isolates of Gram-positive bacteria, vancomycin and teicoplanin were active. Additionally, arbekacin was active against S. aureus clinical isolates and ampicillin was active against E. faecalis clinical isolates. Carbapenems were active against clinical isolates of Gram-positive bacteria, except for multi-drug resistant strains of Gram-positive bacteria, such as methicillin-resistant S. aureus. 2. As for clinical isolates of Gram-negative bacteria, meropenem was most active against Enterobacteriaceae among 13 antibiotics tested. Against P. aeruginosa clinical isolates, MIC90 of meropenem was the lowest among 13 antibiotics tested. In addition, resistant rate of meropenem and biapenem against P. aeruginosa clinical isolates was lower than those of the other carbapenems tested. 3. As main urinary pathogens showed no remarkable increase in resistance to carbapenems, it can be stated that carbapenems retain their position as the drug of first choice for severe infection.
采用琼脂稀释法,对包括4种碳青霉烯类抗生素在内的18种抗生素针对2002年1月至12月期间到鹿儿岛大学医院泌尿外科就诊的尿路感染患者分离出的101株尿路病原菌的抗菌活性进行了研究。检测了4株金黄色葡萄球菌、3株葡萄球菌属(不包括金黄色葡萄球菌)、14株粪肠球菌、3株肠球菌属(不包括粪肠球菌)、41株大肠埃希菌、21株肠杆菌科细菌(不包括大肠埃希菌)、12株铜绿假单胞菌和3株非发酵革兰阴性杆菌(不包括铜绿假单胞菌)。1. 对于革兰阳性菌的临床分离株,万古霉素和替考拉宁具有活性。此外,阿贝卡星对金黄色葡萄球菌临床分离株具有活性,氨苄西林对粪肠球菌临床分离株具有活性。碳青霉烯类抗生素对革兰阳性菌的临床分离株具有活性,但对耐甲氧西林金黄色葡萄球菌等革兰阳性菌的多重耐药菌株除外。2. 对于革兰阴性菌的临床分离株,美罗培南在13种受试抗生素中对肠杆菌科细菌的活性最强。对于铜绿假单胞菌临床分离株,美罗培南的MIC90在13种受试抗生素中最低。此外,美罗培南和比阿培南对铜绿假单胞菌临床分离株的耐药率低于其他受试碳青霉烯类抗生素。3. 由于主要尿路病原菌对碳青霉烯类抗生素的耐药性没有显著增加,可以认为碳青霉烯类抗生素仍然是严重感染的首选药物。